1 – 10 of 22
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2025
-
Mark
Patterns of company misconduct, recidivism, and complaint resolution delays : A temporal analysis of UK pharmaceutical industry self-regulation within the European context
(
- Contribution to journal › Article
-
Mark
Pharmaceutical industry payments to patient organizations in Poland : Analysis of the patterns, evolution, and structure of connections
2025) In International journal of social determinants of health and health services 55(2). p.199-212(
- Contribution to journal › Article
-
Mark
Pharmaceutical company promotional payments to English general practices: : longitudinal study
2025) In BJGP open(
- Contribution to journal › Article
-
Mark
Unknowns of drug company payment disclosure : why the UK needs payment transparency legislation
2025) In BMJ Evidence-Based Medicine(
- Contribution to journal › Article
-
Mark
Self-regulation of UK's pharmaceutical industry
(
- Contribution to journal › Debate/Note/Editorial
- 2024
-
Mark
Drug company methodologies used for reporting in the UK pharmaceutical industry payment transparency database between 2015 and 2019 : A content analysis
(
- Contribution to journal › Article
-
Mark
Payments to healthcare organisations reported by the medical device industry in Europe from 2017 to 2019 : An observational study
(
- Contribution to journal › Article
-
Mark
Broken beyond repair: self regulation of industry payments to clinicians and hospitals
(
- Contribution to journal › Debate/Note/Editorial
- 2023
-
Mark
International comparison of pharmaceutical industry payment disclosures in the UK and Japan: implications for self-regulation, public regulation, and transparency
(
- Contribution to journal › Article
-
Mark
Pharmaceutical industry payments to NHS trusts in England : A four-year analysis of the Disclosure UK database
(
- Contribution to journal › Article